Save up -80% on Umeclidinium
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Incruse Ellipta
|$339.60||1 inhaler (30 blisters) 62.5mcg|
|price without discount in nearest pharmacy. Price may vary.|
We offer free Umeclidinium coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Umeclidinium every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Umeclidinium volume of distribution
For the umeclidinium and vilanterol population-pharmacokinetic analyses, 1,635 and 1,637 patients provided 8,498 and 8,405 observations, respectively. Umeclidinium and vilanterol pharmacokinetics were best described by a two-compartment model with first-order absorption. For umeclidinium, bodyweight, age, and creatinine clearance (CLCR) were statistically significant covariates for apparent inhaled clearance (CL/F); bodyweight was a statistically significant covariate for volume of distribution of central compartment (V 2/F).The population parameter estimates namely CL/F and V 2/F for umeclidinium were 218 L/h and 1,160 L and 40.9 L/h and 268 L for vilanterol. For vilanterol, bodyweight and age were statistically significant covariates for CL/F. The effect of covariates on umeclidinium and vilanterol systemic exposure was marginal. The population model indicates that a 10 % increase in bodyweight will result in a 2 % increase in CL/F for umeclidinium and vilanterol and 6 % increase in umeclidinium V 2/F. A 10 % increase in age will provide a 7 and 4 % decrease in umeclidinium and vilanterol CL/F, respectively. A 10 % decrease in CLCR will result in a 3 % decrease in umeclidinium CL/F. Umeclidinium and vilanterol population-pharmacokinetic model-based systemic exposure predictions showed no pharmacokinetic interactions between umeclidinium and vilanterol when administered in combination.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Umeclidinium
Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). It is available as a once-daily inhalation monotherapy or as a fixed-dose combination product with the long-acting beta2-agonist vilanterol. COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory volume in 1 second (FEV1) of less than 80%. By blocking the M3 muscarinic receptor which is highly expressed in airway smooth muscle of the lungs, umeclidinium inhibits the binding of acetylcholine and thereby opens up the airways by preventing bronchoconstriction. Its use has been shown to provide clinically significant, sustained improvements in lung function.
Umeclidinium mechanism of action
Umeclidinium is a long-acting, antimuscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through the inhibition of M3 receptor at the smooth muscle leading to bronchodilation.
Dosage forms of Umeclidinium
|Incruse Ellipta||62.5mcg||30doses Powder Inhalation||$90.00|
|Incruse Ellipta||62.5mcg||60doses Powder Inhalation||$167.00|
|Incruse Ellipta||62.5mcg||90doses Powder Inhalation||$242.00|
|Anoro Ellipta||55/22mcg||30doses Dry Powder Inhaler||$120.00|
|Anoro Ellipta||55/22mcg||90doses Dry Powder Inhaler||$346.00|
|Trelegy Ellipta||92/55/22mcg||30 doses Inhalation Powder||$133.00|
|Trelegy Ellipta||92/55/22mcg||90 doses Inhalation Powder||$366.00|
Humans and other mammals
Indication of Umeclidinium
Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
Toxicity of Umeclidinium
In clinical trials, the most common adverse effects of umeclidinium were nasopharyngitis, upper respiratory tract infection, cough, and arthralgia. Atrial fibrillation occurred in 1% of patients, but was more common among patients treated with umeclidinium than in those treated with placebo. Anticholinergics like umeclidinium should be used with caution in patients with narrow-angle glaucoma and in those with prostatic hyperplasia or bladder-neck obstruction. Inhaled medications can cause paradoxical bronchospasm, which can be fatal.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Umeclidinium on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.
Get lower price on Umeclidinium now!
What is a Incruse Ellipta?
Incruse Ellipta is an anticholinergic that works by relaxing muscles in the airways to improve breathing.
Incruse Ellipta is used to prevent airflow obstruction or bronchospasm in people with COPD (chronic obstructive pulmonary disease).
Incruse Ellipta is not a life-saving medicine. It will not work fast enough to treat bronchospasm. Use only a fast-acting inhalant to attack.